AbbVie is launching Humira on the TrumpRx platform with an 86% discount under a pricing agreement with the White House. The ...
Humira will be available on TrumpRx at an 86% discount, according to media reports, as part of AbbVie's deal with the White House to avoid tariffs. The news comes less than a week after the president ...
13hon MSNOpinion
The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.
We can start with laws that limit the power of pharmacy-benefit managers ...
Spun off from a Dividend King in 2013, this pharmaceutical stock is a rising star among dividend growth stocks.
HealthDay on MSN
More drugmakers join TrumpRx
Key Takeaways Two more drugmakers have joined President Donald Trump's discount drug programOne drug's price will drop from ...
Prescriptions for an adalimumab biosimilar among new users rose from 0% to 24% after CVS Caremark added it to its formulary, ...
Two more drug-making giants, Abbvie and Genentech, will start selling popular medications on the White House's discounted ...
AbbVie stock is a "Buy" given its Q4 beat, Skyrizi/Rinvoq growth, and strong FCF. Here's what investors need to know about ...
GlobalData on MSN
Insmed freezes Brinsupri’s HS programme on Phase II failure
The DPP1 inhibitor did not beat placebo in this trial, leaving branded Bimzelx and Cosentyx, as well as Humira and its generics to reign across the HS market.
Just The News on MSN
Two more major pharmaceutical companies to launch products through TrumpRx
The companies Abbvie and Genentech are expected to become the 10th and 11th drug-making companies to release their products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results